Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;25(10):1361-1371.
doi: 10.1007/s11886-023-01954-y. Epub 2023 Sep 12.

Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation

David Meier #  1 , Mariama Akodad #  2 , Georgios Tzimas  1 , Olivier Muller  1 , Anson Cheung  3   4 , David A Wood  3   4 , Philipp Blanke  3   4 , Janarthanan Sathananthan  3   4   5 , Fabien Praz  6 , Robert H Boone  3   4 , John G Webb  7   8
Affiliations
Review

Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation

David Meier et al. Curr Cardiol Rep. 2023 Oct.

Abstract

Purpose of review: Mitral and tricuspid regurgitation represents a clinical challenge. They are associated with a poor prognosis, and many patients are not eligible for conventional surgery. Transcatheter therapies have been the focus of numerous studies and devices over the past decade. Here, we provide a summary of current options for transcatheter treatment of these 2 entities.

Recent findings: Recent studies have demonstrated the benefits of edge-to-edge repair for increasing numbers of patients. Encouraging early results with transcatheter valve replacement are also becoming available. To date, transcatheter edge-to-edge repair is currently the first-line transcatheter treatment for both mitral and tricuspid regurgitation for many patients who are not candidates for surgery. A number of transcatheter replacement devices are under development and clinical investigation but, for the most part, their current use is limited to compassionate cases or clinical trials.

Keywords: Mitral regurgitation; TEER; TMVR; TTVR; Transcatheter edge to edge repair; Transcatheter valve replacement; Tricuspid regurgitation.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance
    1. Tung M, Nah G, Tang J, Marcus G, Delling FN. Valvular disease burden in the modern era of percutaneous and surgical interventions: the UK Biobank. Open Heart 2022;9.
    1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35–71. - PubMed
    1. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632. - PubMed - DOI
    1. Mack M, Carroll JD, Thourani V, et al. Transcatheter mitral valve therapy in the United States: a report from the STS-ACC TVT Registry. J Am Coll Cardiol. 2021;78:2326–53. - PubMed - DOI
    1. Stone GW, Abraham WT, Lindenfeld J, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med. 2023;388:2037–48. - PubMed - DOI

MeSH terms

LinkOut - more resources